The company narrowed FY2024 adjusted EPS guidance from prior $3.20 to $3.50, reflecting a challenging retail environment in the U.S., the early wind-down of the sale-leaseback program, and lower earnings due to Cencora share sales, offset by execution in pharmacy services and a lower adjusted effective tax rate.
The company plans to maintain breakeven adjusted EBITDA for U.S. Healthcare, targeting the midpoint of the guidance range of ($50)M to $50M.
More on Walgreens Boots Alliance
- Walgreens Earnings Preview: Revenue Estimates Holding Up; It's A Cost Structure Problem
- Walgreens: One Of The Best Value Picks At The Moment
- Walgreens' Strategic Pivot
- Cost-cutting and lower tax rate likely to help Walgreens meet FQ2 estimates
- Walgreens settles with New York over price gouging on baby formula